Based on this, we further validated the clinical relevance of ACTN1 protein expression using immunohistochemistry and found that ACTN1 expression is negatively correlated with grade II/III gliomas patient prognosis (Fig. 10D–G). This evidence concerns the gene ACTN1 and glioma.